Top

Published in:

Open Access 01-12-2020 | Chloroquin | Research article

Characterization of putative drug resistant biomarkers in Plasmodium falciparum isolated from Ghanaian blood donors

Authors: Enoch Aninagyei, Kwabena Obeng Duedu, Tanko Rufai, Comfort Dede Tetteh, Margaretta Gloria Chandi, Paulina Ampomah, Desmond Omane Acheampong

Published in: BMC Infectious Diseases | Issue 1/2020

Abstract

Background

Plasmodium falciparum parasites, which could harbour anti-malaria drug resistance genes, are commonly detected in blood donors in malaria-endemic areas. Notwithstanding, anti-malaria drug resistant biomarkers have not been characterized in blood donors with asymptomatic P. falciparum infection.

Methods

A total of 771 blood donors were selected from five districts in the Greater Accra Region, Ghana. Each donor sample was screened with malaria rapid diagnostic test (RDT) kit and parasitaemia quantified microscopically. Dried blood spots from malaria positive samples were genotyped for P. falciparum chloroquine resistance transporter (Pfcrt), P. falciparum multi-drug resistance (Pfmdr1), P. falciparum dihydropteroate-synthetase (Pfdhps), P. falciparum dihydrofolate-reductase (Pfdhfr) and Kelch 13 propeller domain on chromosome 13 (Kelch 13) genes.

Results

Of the 771 blood donors, 91 (11.8%) were positive by RDT. Analysis of sequence reads indicated successful genotyping of Pfcrt, Pfmdr1, Pfdhfr, Pfdhps and Kelch 13 genes in 84.6, 81.3, 86.8, 86.9 and 92.3% of the isolates respectively. Overall, 21 different mutant haplotypes were identified in 69 isolates (75.8%). In Pfcrt, CVIET haplotype was observed in 11.6% samples while in Pfmdr1, triple mutation (resulting in YFN haplotype) was detected in 8.1% of isolates. In Pfdhfr gene, triple mutation resulting in IRNI haplotype and in Pfdhps gene, quintuple mutation resulting in AGESS haplotype was identified in 17.7% parasite isolates. Finally, five non-synonymous Kelch 13 alleles were detected; C580Y (3.6%), P615L (4.8%), A578S (4.8%), I543V (2.4%) and A676S (1.2%) were detected.

Conclusion

Results obtained in this study indicated various frequencies of mutant alleles in Pfcrt, Pfmdr1, Pfdhfr, Pfdhps and Kelch 13 genes from P. falciparum infected blood donors. These alleles could reduce the efficacy of standard malaria treatment in transfusion-transmitted malaria cases. Incorporating malaria screening into donor screening protocol to defer infected donors is therefore recommended.

Bruce-Chwatt LJ. Transfusion malaria revisited. Trop Dis Bull. 1982;79:827–40.PubMed

Owusu-Ofori AK, Betson M, Parry CM, Stothard R, Bates I. Transfusion-transmitted malaria in Ghana. Clin Infect Dis. 2013;56(12):1735–41.PubMedCrossRef

Owusu-Ofori A, Gadzo D, Bates I. Transfusion-transmitted malaria: donor prevalence of parasitaemia and a survey of healthcare workers knowledge and practices in a district hospital in Ghana. Malar J. 2016;15(1):234.PubMedPubMedCentralCrossRef

Adusei KA, Owusu-Ofori A. Prevalence of Plasmodium parasitaemia in blood donors and a survey of the knowledge, attitude and practices of transfusion malaria among health workers in a hospital in Kumasi, Ghana. PLoS One. 2018;13(11):e0206303 https://doi.org/10.1371/journal.pone.0206303.PubMedPubMedCentralCrossRef

Mardani A, Keshavarz H, Pourfathollah AA, Maghsudlu M. Transfusion transmitted malaria in Iran: a narrative review article. Iran J Parasitol. 2016;11(2):136–43.PubMedPubMedCentral

Vareil MO, Tandonnet O, Chemoul A, Bogreau H, Saint-Léger M, Micheau M, Millet P, Koeck JL, Boyer A, Rogier C, Malvy D. Unusual transmission of Plasmodium falciparum, Bordeaux, France, 2009. Emerg Infect Dis. 2011;17:248–50.PubMedPubMedCentralCrossRef

Kitchen AD, Barbara JAJ, Hewit PE. Documented cases of post-transfusion malaria occurring in England: a review in relation to current and proposed donor-selection guidelines. Vox Sang. 2005;89:77–80.PubMedCrossRef

Verra F, Angheben A, Martello E, Giorli G, Perandin F, Bisoffi Z. A systematic review of transfusion-transmitted malaria in non-endemic areas. Malar J. 2018;17(1):36. https://doi.org/10.1186/s12936-018-2181-0.PubMedPubMedCentralCrossRef

Mungai M, Tegtmeier G, Chamberland M, Parise M. Transfusion-transmitted malaria in the United States from 1963 through 1999. N Engl J Med. 2001;344:1973–8.PubMedCrossRef

10.

Chattopadhyay R, Majam VF, Kumar S. Survival of Plasmodium falciparum in human blood during refrigeration. Transfusion. 2010. https://doi.org/10.1111/j.1537-2995.2010.02872.x.

11.

Seed CR, Kitchen A, Davis TM. The current status and potential role of laboratory testing to prevent transfusion-transmitted malaria. Transfus Med Rev. 2005;19:229–40.PubMedCrossRef

12.

Wylie BR. Transfusion transmitted infection: viral and exotic diseases. Anaesth Intensive Care. 1993;31:24–30.CrossRef

13.

Manske M, Miotto O, Campino S, Auburn S, Almagro-Garcia J, Maslen G, et al. Analysis of Plasmodium falciparum diversity in natural infections by deep sequencing. Nature. 2012;487:375–9.PubMedPubMedCentralCrossRef

14.

Ekland EH, Fidock DA. Advances in understanding the genetic basis of antimalarial drug resistance. Curr Opin Microbiol. 2007;10:363–70.PubMedPubMedCentralCrossRef

15.

Fidock DA, Nomura T, Talley AK, Cooper RA, Dzekunov SM, Ferdig MT, et al. Mutations in the P falciparum digestive vacuole transmembrane protein PfCRT and evidence for their role in chloroquine resistance. Mol Cell. 2000;6:861–71.PubMedPubMedCentralCrossRef

16.

Foote SJ, Kyle DE, Martin RK, Oduola AM, Forsyth K, Kemp DJ, et al. Several alleles of the multidrug-resistance gene are closely linked to chloroquine resistance in Plasmodium falciparum. Nature. 1990;345:255–8.PubMedCrossRef

17.

Wang P, Lee CS, Bayoumi R, Djimde A, Doumbo O, Swedberg G, et al. Resistance to antifolates in Plasmodium falciparum monitored by sequence analysis of dihydropteroate synthetase and dihydrofolate reductase alleles in a large number of field samples of diverse origins. Mol Biochem Parasitol. 1997;89:161–77.PubMedCrossRef

18.

Chusacultanachai S, Thiensathit P, Tarnchompoo B, Sirawaraporn W, Yuthavong Y. Novel antifolate resistant mutations of Plasmodium falciparum dihydrofolate reductase selected in Escherichia coli. Mol Biochem Parasitol. 2002;120:61–72.PubMedCrossRef

19.

Jiang T, Chen J, Fu H, Kai W, Yao Y, Eyi JUM, et al. High prevalence of Pfdhfr–Pfdhps quadruple mutations associated with sulfadoxine–pyrimethamine resistance in Plasmodium falciparum isolates from Bioko Island, Equatorial Guinea. Malar J. 2019;18:101. https://doi.org/10.1186/s12936-019-2734-x.PubMedPubMedCentralCrossRef

20.

Ariey F, Witkowski B, Amaratunga C, Beghain J, Langlois AC, Khim N, et al. A molecular marker of artemisinin-resistant Plasmodium falciparum malaria. Nature. 2014;505:50–5.PubMedCrossRef

21.

Hanboonkunupakarn B, White NJ. The threat of artemisinin resistant malaria in Southeast Asia. Travel Med Infect Dis. 2016;14(6):548–50. https://doi.org/10.1016/j.tmaid.2016.11.016.PubMedPubMedCentralCrossRef

22.

Dieng CC, Gonzalez L, Pestana K, Dhikrullahi SB, Amoah LE, Afrane YA, Lo E. Contrasting asymptomatic and drug resistance gene prevalence of Plasmodium falciparum in Ghana: implications on seasonal malaria chemoprevention. Genes (Basel). 2019;10(7):538. https://doi.org/10.3390/genes10070538.CrossRef

23.

Matrevi SA, Opoku-Agyeman P, Quashie NB, Bruku S, Abuaku B, Koram KA, Fox A, Letizia A, Duah-Quashie NO. Plasmodium falciparum kelch propeller polymorphisms in clinical isolates from Ghana from 2007 to 2016. Antimicrob Agents Chemother. 2019;63:e00802–19 https://doi.org/10.1128/AAC.00802-19.PubMedPubMedCentralCrossRef

24.

Aninagyei E, Smith-Graham S, Boye A, Acheampong DO. Evaluating 18s-rRNA LAMP and selective whole genome amplification (sWGA) assay in detecting asymptomatic Plasmodium falciparum infections in blood donors. Malar J. 2019;18:214. https://doi.org/10.1186/s12936-019-2850-7.PubMedPubMedCentralCrossRef

25.

WHO. Guidelines on assessing donor suitability for blood donation. World Health Organization 2012. http://www.who.int/iris/handle/10665/76724. Assessed on 7 August 2018.

26.

WHO: Guidelines on drawing blood: Best practices in phlebotomy. 2010.

27.

WHO. Basic Malaria Microscopy: Part I Learner’s guide, World Health Organization, Geneva, Switzerland, 1991.

28.

Oyola SO, Ariani CV, Hamilton WL, Kekre M, Amenga-Etego LN, Ghansah A, Rutledge GG, Redmond S, Manske M, Jyothi D, Jacob CG, Otto TD, Rockett K, Newbold CI, Berriman M, Kwiatkowski DP. Whole genome sequencing of Plasmodium falciparum from dried blood spots using selective whole genome amplification. Malar J. 2016;15:597. https://doi.org/10.1186/s12936-016-1641-7.PubMedPubMedCentralCrossRef

29.

Ochong EO, van den Broek IV, Keus K, Nzila A. Short report: association between chloroquine and amodiaquine resistance and allelic variation in the Plasmodium falciparum multiple drug resistance 1 gene and the chloroquine resistance transporter gene in isolates from the upper Nile in southern Sudan. Am J Trop Med Hyg. 2003;69:84–187.

30.

Basco LK, Ndounga M, Ngane VF, Soula G. Molecular epidemiology of malaria in Cameroon. XIV. Plasmodium falciparum chloroquine resistance transporter (PFCRT) gene sequences of isolates before and after chloroquine treatment. Am J Trop Med Hyg. 2002;67:392–5.PubMedCrossRef

31.

Ehrhardt S, Eggelte TA, Kaiser S, Adjei L, Burchard GD, Anemana SD, Bienzle U, Mockenhaupt FP. Large-scale surveillance of Plasmodium falciparum crt(K76T) in northern Ghana. Antimicrob Agents Chemother. 2007;51(9):3407–9. https://doi.org/10.1128/AAC.00179-07.PubMedPubMedCentralCrossRef

32.

Afoakwah R, Boampong JN, Egyir-Yawson A, Nwaefuna EK, Verner ON, Asare KK. High prevalence of PfCRT K76T mutation in Plasmodium falciparum isolates in Ghana. Acta Trop. 2014;136:32–6.PubMedCrossRef

33.

Yaqoob A, Khattak AA, Nadeem MF, Fatima H, Mbambo G, Ouattara A, Adams M, Zeeshan N, Takala-Harrison S. Prevalence of molecular markers of sulfadoxine–pyrimethamine and artemisinin resistance in Plasmodium falciparum from Pakistan. Malar J. 2018;17:471. https://doi.org/10.1186/s12936-018-2620-y.PubMedPubMedCentralCrossRef

34.

MalariaGEN Plasmodium falciparum Community Project. Genomic epidemiology of artemisinin resistant malaria. Elife. 2016;5:e08714. https://doi.org/10.7554/eLife.08714.CrossRef

35.

Bacon DJ, McCollum AM, Griffing SM, Salas C, Soberon V, Santolalla M, Haley R, Tsukayama P, Lucas C, Escalante AA, Udhayakumar V. Dynamics of malaria drug resistance patterns in the Amazon basin region following changes in Peruvian national treatment policy for uncomplicated malaria. Antimicrob Agents Chemother. 2009;53(5):2042–51.PubMedPubMedCentralCrossRef

36.

Aponte S, Guerra AP, Álvarez-Larrotta C, Bernala SD, Restrepo C, González C, Yasnot MF, Knudson-Ospinad A. Baseline in vivo, ex vivo and molecular responses of Plasmodium falciparum to artemether and lumefantrine in three endemic zones for malaria in Colombia. Trans R Soc Trop Med Hyg. 2017:1–10. https://doi.org/10.1093/trstmh/trx021.

37.

Chenet SM, Akinyi Okoth S, Huber CS, et al. Independent emergence of the Plasmodium falciparum Kelch propeller domain mutant allele C580Y in Guyana. J Infect Dis. 2016;213(9):1472–5. https://doi.org/10.1093/infdis/jiv752.PubMedCrossRef

38.

Straimer J, Gnadig NF, Witkowski B, Amaratunga C, Duru V, Ramadani AP, et al. Drug resistance. K13-propeller mutations confer artemisinin resistance in Plasmodium falciparum clinical isolates. Science. 2015; 347(6220):428±31. doi: https://doi.org/10.1126/science.1260867.

39.

Imwong M, Jindakhad T, Kunasol C, Sutawong K, Vejakama P, Dondorp AM. An outbreak of artemisinin resistant falciparum malaria in eastern Thailand. Sci Rep. 2015;5:17412. https://doi.org/10.1038/srep17412.PubMedPubMedCentralCrossRef

40.

Spring MD, Lin JT, Manning JE, Vanachayangkul P, Somethy S, Bun R, et al. Dihydroartemisinin-piperaquine failure associated with a triple mutant including kelch13 C580Y in Cambodia: an observational cohort study. Lancet Infect Dis. 2015;15:683–91.PubMedCrossRef

41.

Feng J, Li J, Yan H, Feng MY, Xia ZG. Evaluation of antimalarial resistance, marker polymorphism in returned migrant Workers in China. Antimicrob Agents Chemother. 2015;59:326–30. https://doi.org/10.1128/AAC.04144-14.PubMedCrossRef

42.

Huang F, Takala-Harrison S, Jacob CG, Liu H, Sun X, Yang H, et al. A single mutation in K13 predominates in southern China and is associated with delayed clearance of Plasmodium falciparum following artemisinin treatment. J Infect Dis. 2015;212:1629–35.PubMedPubMedCentralCrossRef

43.

Berzosa P, Esteban-Cantos A, García L, González V, Navarro M, Fernández T, Romay-Barja M, Herrador Z, Rubio JM, Ncogo P, Santana-Morales M, Valladares B, Riloha M, Benito A. Profile of molecular mutations in pfdhfr, pfdhps, pfmdr1, and pfcrt genes of Plasmodium falciparum related to resistance to different anti-malarial drugs in the Bata District (Equatorial Guinea). Malar J. 2017;16:28. https://doi.org/10.1186/s12936-016-1672-0.PubMedPubMedCentralCrossRef

44.

Venkatesan M, Gadalla NB, Stepniewska K, Dahal P, Nsanzabana C, Moriera C, et al. Polymorphisms in Plasmodium falciparum chloroquine resistance transporter and multidrug resistance 1 genes: parasite risk factors that affect treatment outcomes for P. falciparum malaria after artemether-lumefantrine and artesunate-amodiaquine. Am J Trop Med Hyg. 2014;91(4):833–43.PubMedPubMedCentralCrossRef

45.

Kwansa-Bentum B, Ayi I, Suzuki T, Otchere J, Kumagai T, Anyan WK, et al. Plasmodium falciparum isolates from southern Ghana exhibit polymorphisms in the SERCA-type PfATPase6 though sensitive to artesunate in vitro. Malar J. 2011;10(187). https://doi.org/10.1186/1475-2875-10-187.

46.

Ayogu EE, Ukwe CV, Mgbeahurike AC, Nna EO. Prevalence of Pfmdr1 86y and 184f alleles is associated with recurrent parasitemia following treatment of uncomplicated malaria with artemether-lumefantrine in Nigerian patients. J App Pharm Sci. 2016;6(04):015–21.

47.

Rajab JA, Waithaka PM, Orinda DAO, Scott CS. Analysis of cost and effectiveness of pre-transfusion screening of donor blood and antimalarial prophylaxis for recipients. East Afr Med J. 2005;82(11):565–71.PubMed

48.

Kweku M, Ofori M, Takramah W, Axame WK, Owusu R, Parbey P, Adjuik M, Tarkang E. Prevalence of malaria and anaemia among pregnant women attending antenatal Care Clinic in the Hohoe Municipality of Ghana. Int J Nurs Didactics. 2017;7 https://doi.org/10.15520/ijnd.2017.vol7.iss7.240.21-30.

49.

Desai M, ter Kuile FO, Nosten F, McGready R, Asamoa K, Brabin B, Newman RD. Epidemiology and burden of malaria in pregnancy. Lancet Infect Dis. 2007;7:93–104.PubMedCrossRef

50.

Guyatt HL, Snow RW. Impact of malaria during pregnancy on low birth weight in sub-Saharan Africa. Clin Microbiol Rev. 2004;17:760.PubMedPubMedCentralCrossRef

51.

World Health Organization: A strategic framework for malaria prevention and control during pregnancy in the African region. Brazzaville: Regional Office for Africa; 2004. AFR/MAL/04/01.

52.

Happi CT, Gbotosho GO, Folarin OA, Akinboye DO, Yusuf BO, Ebong OO, et al. Polymorphisms in Plasmodium falciparum dhfr and dhps genes and age related in vivo sulfadoxine–pyrimethamine resistance in malaria infected patients from Nigeria. Acta Trop. 2005;95:183–93.PubMedCrossRef

53.

Sutherland CJ, Lansdell P, Sanders M, Muwanguzi J, van Schalkwyk DA, Kaur H, Nolder D, Tucker J, Bennett HM, Otto TD, Berriman M, Patel TA, Lynn R, Gkrania-Klotsas E, Chiodini PL. pfk13-independent treatment failure in four imported cases of Plasmodium falciparum malaria treated with artemether-lumefantrine in the United Kingdom. Antimicrob Agents Chemother. 2017;61:e02382–16. https://doi.org/10.1128/AAC.02382-16.PubMedPubMedCentralCrossRef

54.

Henriques G, Hallett RL, Beshir KB, Gadalla NB, Johnson RE, Burrow R, van Schalkwyk DA, Sawa P, Omar SA, Clark TG, Bousema T, Sutherland CJ. Directional selection at the pfmdr1, pfcrt, pfubp1, and pfap2mu loci of Plasmodium falciparum in Kenyan children treated with ACT. J Infect Dis. 2014;210:2001–8. https://doi.org/10.1093/infdis/jiu358.PubMedPubMedCentralCrossRef

Title: Characterization of putative drug resistant biomarkers in Plasmodium falciparum isolated from Ghanaian blood donors
Authors: Enoch Aninagyei
Kwabena Obeng Duedu
Tanko Rufai
Comfort Dede Tetteh
Margaretta Gloria Chandi
Paulina Ampomah
Desmond Omane Acheampong
Publication date: 01-12-2020
Publisher: BioMed Central
Keywords: Chloroquin
Plasmodium Falciparum
Malaria
Chloroquin
Biomarkers
Published in: BMC Infectious Diseases / Issue 1/2020
Electronic ISSN: 1471-2334
DOI: https://doi.org/10.1186/s12879-020-05266-2

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Characterization of putative drug resistant biomarkers in Plasmodium falciparum isolated from Ghanaian blood donors

Abstract

Background

Methods

Results

Conclusion

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2020

Modelling of viral load dynamics and CD4 cell count progression in an antiretroviral naive cohort: using a joint linear mixed and multistate Markov model

Disseminated Mycobacterium abscessus subsp. massiliense infection in a Good’s syndrome patient negative for human immunodeficiency virus and anti-interferon-γ autoantibody: a case report

Gastrointestinal symptoms in invasive pneumococcal disease: a cohort study

Double-carbapenem therapy in the treatment of multidrug resistant Gram-negative bacterial infections: a systematic review and meta-analysis

Prevalence estimates of human immunodeficiency virus (HIV) infection among visceral leishmaniasis infected people in Northwest Ethiopia: a systematic review and meta-analysis

Detection of Beijing strains of MDR M. tuberculosis and their association with drug resistance mutations in katG, rpoB, and embB genes

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page